ClinicalTrials.gg
RecruitingNCT06776601Updated Jan 15, 2025

Digital Therapy in Self-management of COPD Patients

An interventional study of Full process digital therapy intervention package in Chronic Obstructive Pulmonary Disease, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jul 2024, registered Dec 2024).
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital — 16 open to participants now, 17 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · China-Japan Friendship Hospital.

Planned enrollment
4th of 13
600 · median 360
Started
2024
with 4 others
No phase
13 of 24
9 open now
Primary completion
2025-09
later than 7 of 16 live
Registered
20th of 24
by date

Among the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2024, is one of 13 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 20th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

16 of the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital, or all of them as a file.
02

Study summary

This project adopts a whole-process digital therapy intervention package composed of an inhalation technique assessment device, an electronic inhalant medication monitoring device and digital software to guide patients use the inhaler correctly personalizedly, record and manage the behavior data of chronic obstructive pulmonary disease (COPD) patients during the use of inhalant medication, and provide personalized reminders and feedback to patients according to the data. The purpose is to analyze whether this digital intervention scheme can reduce the number of acute exacerbations of COPD, improve the management effect of COPD, and reduce the burden of disease by improving the medication compliance of COPD patients.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic obstructive pulmonary disease
  • adherence
  • inhaled medication
  • self management
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with
  2. Aged 40 and above
  3. Had one or more severe acute exacerbations in the past year, and be in stable condition for the last 4 weeks
  4. Can operate a smartphone proficiently
  5. Take inhalation medication suits for the inhalation monitoring device as treatment
  6. Fully understand and be willing to sign the form

Exclusion criteria

Exclusion Criteria:

  1. Certain comorbidities (e.g. unstable coronary complications)
  2. Undergone thoracic, abdominal or ophthalmic surgery in recent 3 months
  3. Pregnant or lactating women
  4. ABS allergy history
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Digital therapy intervention group

    Patients will receive individualized inhalation skills guidance after being tested by inhalation capacity measuring device, and be equipped with electronic inhalation monitoring devices, which can record their medication using data, reminding patients to use the medication on time, and correct their inhalation mistake. They can also check their inhalation record on their mobile phones. Clinicians can check the record every month to assess their adherence.

    Behavioral: Full process digital therapy intervention package

  • No intervention
    General management group

    Patients will accept regular inhaler medication direction, and equipped with electronic inhalation monitoring that can only record medication using data.

Interventions

  • BehavioralFull process digital therapy intervention package

    Patients will receive individualized inhalation skills guidance after being tested by inhalation capacity measuring device, and be equipped with electronic inhalation monitoring devices, which can record their medication using data, reminding patients to use the medication on time, and correct their inhalation mistake. They can also check their inhalation record on their mobile phones. Clinicians can check the record every month to assess their adherence.

06

What researchers measure

Primary outcomes

  1. severe exacerbation

    Proportion of patients with severe acute exacerbation of COPD pulmonary disease during the follow-up period.

    Time frame: 12 month

Secondary outcomes

  1. First Second Forced Expiratory Volume/ Forced Vital Capacity

    First Second Forced Expiratory Volume/Forced Vital Capacity (FEV1/FVC) measured by pulmonomete, %

    Time frame: 12 month

  2. First Second Forced Expiratory Volume percentage of estimated

    First Second Forced Expiratory Volume (FEV1) percentage of estimated measured by pulmonomete, %

    Time frame: 12 month

  3. peak expiratory flow

    peak expiratory flow (PEF) measured by pulmonomete, L/min

    Time frame: 12 month

  4. COPD Assessment Test score

    COPD assessment test (CAT) is an eight-item questionnaire range from 0 to 40. Higher scroe represents heavier symptom.

    Time frame: 12 month

  5. modified Medical Research Council scale

    The modified Medical Research Council (mMRC) scale stands for the level of patient self-report dyspnea. 0 is the minimum and 4 is the maximum.

    Time frame: 12 month

  6. St. George's Respiratory Questionnairefor chronic obstructive pulmonary disease (SGRQ) score

    the SGRQ scroe range from 0 to 100. 0 represents for the least and 100represents for the most.

    Time frame: 12 month

  7. peak inspiratory flow rate

    peak inspiratory flow rate (PIFR) measured by the sensor in the study

    Time frame: 12 month

  8. mild and moderate exacerbation

    Proportion of patients with mild and moderate acute exacerbation of COPD pulmonary disease during the follow-up period.

    Time frame: 12 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Sep 2025, 14 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 14 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2024
First posted
Jan 15, 2025
StartActual
Jul 18, 2024
Primary completionEst.
Sep 18, 2025
CompletionEst.
Dec 30, 2025
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06776601
Responsible party
Hongtao Niu (PhD, China-Japan Friendship Hospital) — Principal investigator
First posted
Jan 15, 2025
Start date
Jul 18, 2024
Primary completion
Sep 18, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Jan 15, 2025

Study contacts

Hanna Wu, MD
Contact
wuhanna0506@163.com
86+15827502015
Hongtao Niu, PhD
Contact
oxhongtao@163.com
86+15810610306
Hongtao Niu, PhD
principal investigator · China Japan Friendshi Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion